- 1 Spatial and Temporal Distribution of Visceral Leishmaniasis in Karamoja Region,
- 2 Uganda: Analysis of surveillance data, 2015–2022
- 3 **Authors:** Mercy Wendy Wanyana<sup>1\*</sup>, Richard Migisha<sup>1</sup>, Patrick King<sup>1</sup>, Benon Kwesiga<sup>1</sup>,
- 4 Daniel Kadobera<sup>1</sup>, Lilian Bulage<sup>1</sup>, Alex Riolexus Ario<sup>1</sup>
- 5 Institutional affiliations: <sup>1</sup>Uganda Public Health Fellowship Program, Uganda National
- 6 Institute of Public Health, Kampala, Uganda
  - \*Correspondence: Email: <a href="mailto:mwanyana@uniph.go.ug">mwanyana@uniph.go.ug</a>, Tel: +256779207928

### **Abstract**

11

39

41

- 12 **Background:** Uganda targets to control leishmaniasis and eliminate visceral
- leishmaniasis as a public health problem by 2030, with 85% of the cases detected, 95%
- treated, and visceral leishmaniasis eliminated (<1% case fatality rate [CFR]). However,
- little is documented on the country's progress towards achieving these targets. We
- examined the temporal trends and spatial distribution of leishmaniasis in the endemic
- 17 Karamoja Region of Uganda, 2015–2022.
- 18 **Methods:** We analysed aggregate secondary data on clinically diagnosed leishmaniasis
- laboratory-confirmed cases, visceral leishmaniasis cases, hospital admissions, and
- deaths from the District Health Information System 2. We used population-based
- calculations to determine the annual prevalence of leishmaniasis and quarterly
- prevalence of visceral leishmaniasis per 1,000,000 persons, while the prevalence of
- leishmaniasis admissions and CFRs were calculated per 100 cases. We used the
- 24 Mann-Kendall test to assess the significance of the trend.
- 25 **Results:** Overall, 4,008 cases of clinically diagnosed leishmaniasis were reported, and
- of these, 11% were laboratory-confirmed. The average annual prevalence of
- leishmaniasis was 4 per 1,000,000 population. From 2020 to 2022, there was an
- increasing trend in quarterly prevalence of visceral leishmaniasis (Kendall's score=36,
- p=0.016), averaging 3 cases per 1,000,000 population. Leishmaniasis admissions
- increased annually to 55 per 100 cases (Kendall's score=23, p=0.006). The average
- annual CFR was 5%, with no deaths reported in 2018, 2019, and 2021. Amudat District
- had the highest prevalence rates of leishmaniasis (477 per 1,000,000 population) and
- visceral leishmaniasis (139 per 100,000 population).
- 34 **Conclusion:** The increasing trend of visceral leishmaniasis, and CFR >1% threaten the
- goal of controlling leishmaniasis as a public health problem by 2030. Gaps in case
- detection may further prevent the achievement of targets. Strengthening existing
- interventions, such as vector control and rapid diagnostic kits for early detection and
- treatment, may be crucial to sustain progress toward elimination targets.
- 40 **Keywords**: Leishmaniasis, Visceral leishmaniasis, Disease control, Uganda

### Background

43

44

45

46 47

48 49

50

51

52 53

54 55

56

57

58 59

60 61

62

63

64

65

66

67

68

69

70 71

72

73

74 75

76

77 78

79

80

81

82

83

84

85

86

87

Leishmaniasis is a vector-borne neglected tropical disease caused by a protozoan and transmitted by a female sand fly mainly of *Phlebotomus* species<sup>1</sup>. Transmission occurs when an infected female sand fly bites a human host and transmits the parasite to the host during its blood meal<sup>2</sup>. The disease clinically manifests in three forms: cutaneous, mucocutaneous and visceral<sup>3</sup>. Clinical presentation usually depends on the virulence of the parasite, the individual's immunity, and the site of the lesion<sup>4</sup>. The cutaneous form is the mildest form, typically presenting with painless nodules, macules, papules or ulcerative lesions on the skin in areas exposed to bites of the sand fly. It is commonly linked to the Leishamania major and Leishmania tropica species<sup>2</sup>. The mucosal form typically presents with lesions on the mucus membranes and cartilage in the nose, mouth, upper respiratory tract, and pharynx<sup>5</sup>. Visceral leishmaniasis manifests as fever, weight loss, splenomegaly, hepatomegaly, and reduced blood cell production, potentially causing anemia, bleeding, and susceptibility to other infections<sup>6,7</sup> Visceral Leishmaniasis, often associated with L. donovani in East Africa, is highly fatal with a 95% untreated case fatality rate and 10-20% with treatment<sup>8,9</sup>. It carries outbreak potential, with sequelae like relapse and post-kala-azar dermal leishmaniasis, contributing to interepidemic reservoirs and sustaining transmission.

As of 2019, approximately 4,580,000 cases of leishmaniasis were reported globally, causing an estimated 657,000 new cases annually and resulting in 697,000 Disease Adjusted Life Years (DALYs) lost<sup>10</sup>. African countries including Uganda contribute a significant proportion of the burden, accounting for 34-57% <sup>11</sup>. Leishmaniasis disproportionately impacts the poorest populations due to factors such as inadequate housing, poor environmental sanitation, lack of control measures, and economically driven migration to vector-prone areas, increasing their susceptibility to the disease <sup>12,13</sup>. Children and immunocompromised individuals, including People Living with HIV (PLWHIV), are more affected than adults and non-immunocompromised individuals<sup>14,15</sup>.

Leishmaniasis places a catastrophic financial burden on affected households with a median cost ranging from USD 165 to 1,500 per episode<sup>13,16</sup>. To avert this burden. current global efforts aim at controlling leishmaniasis and eliminate leishmaniasis by 2030 through the World Health Organization(WHO) Roadmap for neglected tropical diseases 2021–2030<sup>17</sup>. Specifically, this aims to ensure that 85% of all leishmaniasis cases are detected, 95% treated, and visceral leishmaniasis eliminated (<1% case fatality rate [CFR]); this includes Uganda where the disease is endemic especially in the Karamoja Region. Currently there is a paucity of data on the country's progress and burden of leishmaniasis. This could be attributed to the limited analysis of surveillance data despite it's being in the national integrated disease surveillance system. 18 Analysis of the surveillance data is key to detect remaining or re-emerging hotspots of leishmaniasis transmission which supports timely adaptation of control and elimination interventions<sup>19</sup>. Given the complexity of leishmaniasis management and diagnostics, control efforts adopt an innovative and intensified disease management approach. emphasizing individual care at health facilities<sup>20</sup>. As such, understanding trends in health facility leishmaniasis data is crucial for evidence-based decision-making. We

- 88 examined the temporal trends and spatial distribution of leishmaniasis in the endemic
- 89 Karamoja Region of Uganda, 2015–2022.
- 90 Methods

99

### Study settings

- We utilised leishmaniasis surveillance data generated from all health facilities in the
- Saramoja region in the years 2015–2022. Leishmaniasis is endemic in the Karamoja
- region in Uganda. The semi-arid climate and termite hills in this region provide a
- 95 favourable environment for sand flies of *Phlebotomus* species which are the vector
- responsible for transmission of Visceral Leishmaniasis<sup>21</sup>. Within Uganda health facilities
- 97 leishmaniasis is diagnosed clinically and confirmed using a Giemsa-stain slides viewed
- 98 under a microscope.

### Study design and data Source

- 100 We conducted a descriptive study using routinely collected leishmaniasis surveillance
- data collected in District Health Information System 2 (DHIS-2) .The DHIS-2 collects
- data on diseases of public health importance like leishmaniasis based on the Integrated
- Disease Surveillance and response guidelines.<sup>22</sup> It includes data on both clinically
- diagnosed and laboratory confirmed leishmaniasis cases, admissions, primary visceral
- leishmaniasis i.e. without history of visceral leishmaniasis treatment, relapse i.e. with
- history of visceral leishmaniasis treatment, post-kala-azar dermal leishmaniasis, a
- complication of visceral leishmaniasis and leishmaniasis HIV co-infection, and deaths.
- Before 2020, all forms of leishmaniasis (cutaneous, visceral and mucosal) were
- reported jointly in the monthly outpatient and in-patient registers. In 2020, an in-patient
- tool that collects primary visceral leishmaniasis, relapse and leishmaniasis HIV co-
- infection was introduced. In this study, we utilized aggregate data of on leishmaniasis
- from monthly outpatient reports (Health Management Information System forms [HMIS]
- 105) 2015–2022, inpatient monthly reports (HMIS 108) 2015–2022, and (HMIS 127b)
- 114 2020–2022.

115

### Study variables, data management, and analysis

- We downloaded the data regarding clinically-diagnosed and laboratory-confirmed
- leishmaniasis cases and admissions, primary visceral leishmaniasis, relapse visceral
- leishmaniasis, post-kala-azar dermal leishmaniasis, and visceral leishmaniasis HIV co-
- infection, and death.in excel and imported in STATA version 16 software (StataCorp,
- 120 College Station, Texas, USA) for analysis. Using data on leishmaniasis and visceral
- leishmaniasis cases, we calculated the annual prevalence of leishmaniasis as
- laboratory confirmed leishmaniasis cases divided by the population in the region. From
- 2020 to 2022, we assessed the proportions of primary, relapse, post-kala-azar dermal
- leishmaniasis, and HIV co-infection among admitted Visceral Leishmaniasis cases.
- 125 Quarterly prevalence of Visceral Leishmaniasis was calculated as the ratio of primary
- and relapse cases to the population, obtained from Uganda Bureau of Statistics.
- Leishmaniasis admissions and hospitalization prevalence were determined using

- leishmaniasis cases as denominators. Case fatality rates were computed based on the
- proportion of deceased leishmaniasis cases. Line graphs were used to show trends,
- and Mann-Kendall test to assess the significance of trends. We used choropleth maps
- created with QGIS software to illustrate the spatial distribution of leishmaniasis in the
- 132 region.

### **Ethical Considerations**

- Our study utilized routinely generated aggregated surveillance data with no personal
- identifiers in health facility outpatient and in-patient monthly reports, obtained from the
- DHIS-2. The Uganda Public Health Fellowship Program is part of the National Rapid
- 137 Response Team, and has been granted permission to access and analyse surveillance
- data in the DHIS-2 and other data such as survey and field investigation data to inform
- decision making in the control and prevention of outbreaks and public health
- programming. Additionally, the Ministry of Health (MoH) has also granted the program
- permission to disseminate the information through scientific publications. We stored the
- abstracted data set in a password-protected computer and only shared it with the
- investigation team. In addition, the Office of the Associate Director for Science, U.S.
- 144 Centers for Disease Control and Prevention, determined that this study was not a
- human subjects research with the primary intent of improving use of surveillance data to
- guide public health planning and practice.
- 147 This activity was reviewed by CDC and was conducted consistent with applicable
- 148 federal law and CDC policy.§
- §See e.g., 45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C. §552a; 44
- 150 U.S.C. §3501 et seq.

### Results

151

152

153

### Trends in the prevalence of leishmaniasis, Karamoja Region, Uganda, 2015-2022

- 154 Reporting rates for the Karamoja region ranged from 96% to 100% during the review
- period (from 2015 to 2022). Overall, 4,008 clinically-diagnosed leishmaniasis cases were
- reported. Of these, 484 (11%) were confirmed. The average annual prevalence of
- leishmaniasis was 4 cases per 1,000,000 population in the Karamoja Region reported
- from 2015 to 2022. No trend in leishmaniasis prevalence was observed, Kendall's score-
- 159 13, p=0.173 (Figure 1).




Figure 1: Trends in annual leishmaniasis prevalence, Karamoja Region, Uganda, 2015–2022

# Trends of the quarterly prevalence of visceral leishmaniasis, Karamoja Region, Uganda, 2020–2022

Over the review period, 602 visceral leishmaniasis cases were reported. Of these 540 (90%) were primary visceral leishmaniasis cases while 62 (10%) were relapse cases. Of the total cases, 4 (1%) were visceral leishmaniasis HIV-coinfected and 5 (1%) were post-kala-azar dermal leishmaniasis. The average quarterly prevalence of visceral leishmaniasis cases was 3 cases per million with the highest prevalence (5 cases per 1,000,000 population) reported in the quarter 3 of 2022 (Figure 2). From 2020 to 2022, there was an increasing trend in the quarterly prevalence of visceral leishmaniasis, Kendall's score=36, p=0.016.




Figure 2: Trends in quarterly prevalence of visceral leishmaniasis, Karamoja Region, Uganda, 2020–2022.

## Trends of leishmaniasis admissions, Karamoja Region, Uganda, 2015–2022

From 2015 to 2022, the average annual prevalence of leishmaniasis admission in the Karamoja region was 52 cases per 100 cases. The highest incidence of leishmaniasis admissions were reported in the years 2020 (87 leishmaniasis admissions per 100 cases), 2021 (93 leishmaniasis admissions per 100 cases), and 2022 (92 leishmaniasis admissions per 100 cases) (Figure 3). Overall there was an increasing trend of leishmaniasis admissions, Kendall's score= 23, p=0.006.




Figure 3: Trends in hospital admissions due to leishmaniasis in Karamoja Region, Uganda, 2015–2022.

### Leishmaniasis case fatality rate, Karamoja region, Uganda, 2015–2022

During the review period, the average annual CFR was 5% (Range: 0-11%), with no deaths reported in 2018, 2019, and 2021. The highest case fatality rates was recorded in 2020. No trends were observed in the case fatality rate, Kendall's score= -2, p=0.947 (Figure 4).





Figure 4: Trends in leishmaniasis case fatality rate, Karamoja Region, Uganda, 2015–2022

# Spatial distribution of Leishmaniasis, Karamoja Region, Uganda, 2015–2022

Within the Karamoja Region, Amudat District reported the highest average annual prevalence of both leishmaniasis (477 per 1,000,000 population) and visceral leishmaniasis (139 per 100,000 population). Abim, Kaabong, Karenga, and Nabilatuk did not report both leishmaniasis and visceral leishmaniasis cases during the reporting period.






Figure 5: Spatial distribution of leishmaniasis and visceral leishmaniasis, Karamoja Region, Uganda, 2015–2022

### **Discussion**

In this analysis to examine the temporal trends and spatial distribution of leishmaniasis in an endemic Karamoja Region of Uganda, 2015–2022, only 11% of the clinically-diagnosed leishmaniasis cases were laboratory confirmed. Over the review period, no changes were observed in the annual prevalence of leishmaniasis. While most visceral leishmaniasis cases were primary, we identified relapse, post-kala-azar dermal leishmaniasis, and visceral leishmaniasis HIV coinfected cases between 2020 and 2022. A rising trend in quarterly prevalence of visceral leishmaniasis occurred from quarter one (Q1) 2020 to quarter four (Q4) 2022, along with an increase in hospital admissions due to leishmaniasis. The average annual CFR remained <1%, with no deaths reported in 2018, 2019, and 2021. Amudat District had the highest leishmaniasis prevalence.

We identified gaps in case detection, with only 11% of clinically-diagnosed cases confirmed by laboratory investigations. Leishmaniasis shares clinical features with common regional illnesses like malaria, typhoid, and tuberculosis, emphasizing the importance of laboratory confirmation in case detection<sup>23</sup>. In the East African region, numerous factors may hinder laboratory confirmation for leishmaniasis including low proportions of health facilities with microscopes and microscopy supplies and trained staff in leishmaniasis testing<sup>24</sup>. Such existing gaps may hinder achievement of leishmaniasis targets of 85% of all leishmaniasis cases detected.

In contrast to the global declining trends in leishmaniasis prevalence, no significant trends were observed in the Karamoja Region for leishmaniasis cases from 2015 to

- 2022<sup>25,26</sup>. The Karamoja Region like the rest of East Africa faces unique challenges that
- may prevent declines despite targets. The Karamoja Region like the rest of East Africa
- faces unique challenges that may prevent declines despite targets, including poor at-
- risk population with limited access to healthcare and insecurity in endemic regions<sup>19</sup>.
- Our findings further indicated an increase in the quarterly prevalence of visceral
- leishmaniasis cases from 2020 to 2022. This trend is similar to global leishmaniasis
- 239 surveillance data that indicated an increase in visceral leishmaniasis in the East African
- 240 Region during 2020<sup>11</sup>. During this period, vital control programs supporting the region,
- such as the Accelerating the Sustainable Control and Elimination of Neglected Tropical
- Diseases, were terminated. This resulted in the scaling down of control efforts<sup>27</sup>. The
- increase in visceral leishmaniasis cases following termination of control programmes
- 244 may undo previous gains towards achievement of elimination targets. Furthermore, we
- found Visceral Leishmaniasis relapse and post-kala-azar dermal leishmaniasis (PKDL)
- cases. The presence of these cases contributes to the maintenance of infectious
- reservoirs, posing a threat to the achievement of elimination targets<sup>28</sup>.
- Our findings revealed a considerable number of hospital admissions due to
- leishmaniasis. This suggests a sustained burden of visceral leishmaniasis whose illness
- and management often requires hospitalisation<sup>29</sup>. Admissions due to leishmaniasis
- impose a substantial economic burden on households, with a median expenditure of
- 450 US dollars per hospital stay due to leishmaniasis<sup>30</sup>. We found that hospital
- 253 admissions linked to leishmaniasis increased. This might suggest gaps in treatment of
- leishmaniasis resulting in leishmaniasis complications that may require in-patient
- admissions.
- The average annual CFR was still greater than the 1% target by 2030. This indicated
- 257 that Uganda is yet to achieve the control leishmaniasis and eliminate visceral
- leishmaniasis as a public health elimination. The no trend observed in CFR and its
- substantial variation in the CFR from 0 to 11% suggests a need for intensifying efforts to
- 260 ensure targets are met. Such efforts include improving prompt diagnosis of visceral
- leishmaniasis using rapid diagnostic kits and increasing access to prompt effective
- 262 treatment.
- In regards to the current distribution, Amudat had the highest prevalence of both
- leishmaniasis and visceral leishmaniasis. This pattern may be attributed to presence of
- a referral leishmaniasis treatment centre at Amudat Hospital<sup>31</sup>.
- Our findings should be interpreted with considerations of the following limitations. Our
- use of facility-based data may lead to an underestimation of the true disease burden.
- 268 capturing only individuals seeking healthcare. Previous studies have indicated that
- surveillance data may underreport the burden of leishmaniasis up to 8 fold for visceral
- leishmaniasis and 5 fold for cutaneous leishmaniasis<sup>9</sup>. Additionally, our reliance on
- 271 aggregate data restricted further exploration of prevalence in population subcategories
- 272 and specific clinical types of leishmaniasis.

Conclusion 273 The current burden of leishmaniasis coupled with gaps in case detection threatens the 274 achievement of control of leishmaniasis targets. While the increasing trends of visceral 275 leishmaniasis and variation in case fatality rates question whether achieved visceral 276 leishmaniasis targets will be met by 2030. Existing interventions should be intensified to 277 including vector control, rapid diagnostic kits for early detection and prompt treatment 278 should be intensified to sustain the achievement of elimination targets. 279 280 List of abbreviations 281 282 CFR: Case Fatality Rate DHIS-2: District Health Information System 2 283 HMIS: Health Management Information System 284 NTD: Neglected Tropical Disease 285 PKDL: Post-kala-azar Dermal Leishmanisis 286 287 288 289 290 291 292 293

### **Acknowledgements**

294

300

301

- We would like to thank the Ministry of Health for providing access to DHIS2 data that
- was used for this analysis. We appreciate the technical support provided by the Division
- of Surveillance, Information and Knowledge Management and the Division of Vector
- 298 Control. Finally, we thank the US-CDC for supporting the activities of the Uganda Public
- 299 Health Fellowship Program.

### References

- 1. Torres-Guerrero E, Quintanilla-Cedillo MR, Ruiz-Esmenjaud J, Arenas R. Leishmaniasis: a review. F1000Research. 2017;6:750.
- Bates PA. Transmission of Leishmania metacyclic promastigotes by phlebotomine sand flies. Int J Parasitol. 2007 Aug;37(10):1097–106.
- 306 3. Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet (London, England). 2018 Sep;392(10151):951–70.
- Mokni M. [Cutaneous leishmaniasis]. Ann Dermatol Venereol. 2019 Mar;146(3):232–46.
- Handler MZ, Patel PA, Kapila R, Al-Qubati Y, Schwartz RA. Cutaneous and mucocutaneous leishmaniasis: Clinical perspectives. J Am Acad Dermatol [Internet]. 2015 Dec 1;73(6):897–908. Available from:
- 313 https://doi.org/10.1016/j.jaad.2014.08.051
- Bi K, Chen Y, Zhao S, Kuang Y, John Wu C-H. Current Visceral Leishmaniasis
   Research: A Research Review to Inspire Future Study. Biomed Res Int.
   2018;2018:9872095.
- 7. van Griensven J, Diro E. Visceral leishmaniasis. Infect Dis Clin North Am. 2012 Jun;26(2):309–22.
- 319 8. Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, et al. Visceral 320 leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev 321 Microbiol [Internet]. 2007;5(11):873–82. Available from: 322 https://doi.org/10.1038/nrmicro1748
- 9. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7(5):e35671.
- 10. IHE (Institute for Health Metrics and Evaluation). Leishmaniasis- Level 3 Cause [Internet]. 2019 [cited 2023 Feb 1]. Available from:
- https://www.healthdata.org/results/gbd\_summaries/2019/leishmaniasis-level-3-cause
- 11. mondiale de la Santé O, Organization WH. Global leishmaniasis surveillance: 2019–2020, a baseline for the 2030 roadmap–Surveillance mondiale de la
- leishmaniose: 2019-2020, une période de référence pour la feuille de route à

- l'horizon 2030. Wkly Epidemiol Rec Relev Épidémiologique Hebd. 2021;96(35):401–19.
- 12. Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. Trends Parasitol. 2006 Dec;22(12):552–7.
- Okwor I, Uzonna J. Social and Economic Burden of Human Leishmaniasis. Am J Trop Med Hyg. 2016 Mar;94(3):489–93.
- 14. Lindoso JAL, Moreira CHV, Cunha MA, Queiroz IT. Visceral leishmaniasis and HIV coinfection: current perspectives. HIV AIDS (Auckl). 2018;10:193–201.
- Gupta AK, Singh A, Srivastava S, Shankar P, Singh S. Visceral Leishmaniasis in children: Diagnosis, treatment, and prevention. J Pediatr Infect Dis.
   2017;12(04):214–21.
- Uranw S, Meheus F, Baltussen R, Rijal S, Boelaert M. The Household Costs of Visceral Leishmaniasis Care in South-eastern Nepal. PLoS Negl Trop Dis
   [Internet]. 2013 Feb 28;7(2):e2062. Available from: https://doi.org/10.1371/journal.pntd.0002062
- 17. Casulli A. New global targets for NTDs in the WHO roadmap 2021–2030. PLoS Negl Trop Dis [Internet]. 2021 May 13;15(5):e0009373. Available from: https://doi.org/10.1371/journal.pntd.0009373
- MoH (Minstry of Health Uganda). Sustainability Plan for Neglected Tropical
   Diseases Control Program [Internet]. Kampala, Uganda; 2020. Available from:
   http://library.health.go.ug/publications/neglected-tropical-diseases/sustainability-plan-neglected-tropical-diseases-control
- 19. Alvar J, den Boer M, Dagne DA. Towards the elimination of visceral leishmaniasis as a public health problem in east Africa: reflections on an enhanced control strategy and a call for action. Lancet Glob Heal. 2021 Dec;9(12):e1763–9.
- Engels D, Zhou X-N. Neglected tropical diseases: an effective global response to local poverty-related disease priorities. Infect Dis Poverty [Internet]. 2020;9(1):10. Available from: https://doi.org/10.1186/s40249-020-0630-9
- 360 21. Jones CM, Welburn SC. Leishmaniasis Beyond East Africa. Front Vet Sci. 2021;8:618766.
- MoH (Minstry of Health Uganda). National Technical Guidelines for Integrated
  Disease Surveillance and Response Third Edition [Internet]. 2021. Available from:
  https://www.afro.who.int/sites/default/files/2021-09/2\_Uganda 3rd IDSR Tech
  Guideline\_PrintVersion\_10Sep2021.pdf
- Thakur S, Joshi J, Kaur S. Leishmaniasis diagnosis: an update on the use of parasitological, immunological and molecular methods. J Parasit Dis Off organ Indian Soc Parasitol. 2020 Jun;44(2):253–72.
- de Souza DK, Picado A, Bessell PR, Liban A, Wachira D, Mwiti D, et al.
  Strengthening Visceral Leishmaniasis Diagnosis Capacity to Improve Access to

- Care in Kenya: The Example of Marsabit County. Front Trop Dis [Internet].
- 372 2022;2. Available from:

- https://www.frontiersin.org/articles/10.3389/fitd.2021.809757
- Alatif H. Burden and Trends of Leishmaniasis over the last one Decade Across the Globe: Trend Analysis of WHO Regions. Integr J Med Sci [Internet]. 2020;8. Available from: https://mbmj.org/index.php/ijms/article/view/295
- Kyu HH, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet [Internet]. 2018 Nov 10;392(10159):1859–922. Available from: https://doi.org/10.1016/S0140-6736(18)32335-3
- 383 27. Makoni M. New threats to visceral leishmaniasis control. The Lancet Microbe
  384 [Internet]. 2021 Nov 1;2(11):e574. Available from: https://doi.org/10.1016/S2666385 5247(21)00285-8
- Duthie MS, Goto Y, Ghosh P, Mondal D. Impact of sequelae of visceral leishmaniasis and their contribution to ongoing transmission of Leishmania donovani. Pathog Dis. 2019 Aug;77(6).
- Moore EM, Lockwood DN. Treatment of visceral leishmaniasis. J Glob Infect Dis. 2010 May;2(2):151–8.
- 30. Meheus F, Abuzaid AA, Baltussen R, Younis BM, Balasegaram M, Khalil EAG, et al. The economic burden of visceral leishmaniasis in Sudan: an assessment of provider and household costs. Am J Trop Med Hyg. 2013 Dec;89(6):1146–53.
- 31. Olobo-Okao J, Sagaki P. Leishmaniasis in Uganda: historical account and a review of the literature. Pan Afr Med J. 2014;18:16.